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After solid organ transplantation, tacrolimus is given to prevent rejection. Therapeutic
drug monitoring is used to reach target concentrations of tacrolimus in whole blood.
Because the site of action of tacrolimus is the lymphocyte, and tacrolimus binds
~80% to erythrocytes, the intracellular tacrolimus concentration in lymphocytes is pos-
sibly more relevant. For this purpose, we aimed to develop, improve and validate a
UPLC–MS/MS method to measure tacrolimus concentrations in isolated peripheral
blood mononuclear cells (PBMCs). PBMCs were isolated using a Ficoll separation tech-
nique, followed by a washing step using red blood cell lysis. A cell suspension of 50μL
containing 1 million PBMCs was used in combination with MagSiMUS‐TDMPREP. To
each sample we added 30μL lysis buffer, 20μL reconstitution buffer containing
13C2H4‐tacrolimus as internal standard, 40μL MagSiMUS‐TDM
PREP Type I Particle
Mix and 175μL Organic Precipitation Reagent VI for methanol‐based protein precipi-
tation. A 10μL aliquot of the supernatant was injected into the UPLC–MS/MS system.
The method was validated, resulting in high sensitivity and specificity. The method was
linear (r2 = 0.997) over the range 5.0–1250 pg/1 × 106 PBMCs. The inaccuracy was
<5% and the imprecision was <15%. The washing steps following Ficoll isolation could
be performed at either room temperature or on ice, with no effect of the temperature
on the results. A method for the analysis of tacrolimus concentrations in PBMCs was
developed and successfully validated. Further research will be performed to investigate
the correlation between concentrations in PBMCs and clinical outcome.
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Immunosuppressive therapy is necessary to prevent acute rejection
after solid organ transplantation. The current drug regimen of first- - - - - - - - - - - - - - - - - - - - - - - - - - -
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2 of 8 BAHMANY ET AL.term patient and allograft survival (Hesselink & Hoorn, 2014; Lamb,
Lodhi, & Meier‐Kriesche, 2011). Tacrolimus is difficult to dose owing
to its narrow therapeutic window and wide inter‐individual variability
in its pharmacokinetics (Kaufman et al., 2004; Matas et al., 2013).
Therefore, treatment with a standard dose is not recommended and
therapeutic drug monitoring (TDM) is routinely used to reach target
predose concentrations in whole blood (Passey et al., 2011; Staatz &
Tett, 2004).
Despite improvements in immunosuppressive treatment proto-
cols, acute cellular rejection remains a concern, with ~10–20% of renal
transplant recipients suffering from an acute rejection in the first
12months after transplantation (Group et al., 2014; Lamb et al.,
2011). This occurs even when whole‐blood tacrolimus concentrations
are within the target range, suggesting that whole‐blood concentra-
tions do not accurately reflect the pharmacological effect (Bouamar
et al., 2013; Capron, Haufroid, & Wallemacq, 2016). The receptor of
tacrolimus is the 12 kDa FK506 binding protein (FKBP12). The
tacrolimus‐FKBP12 complex in turn binds to calcineurin and blocks
the activation of this calcium/calmodulin‐activated phosphatase
within the T‐lymphocyte (Griffith et al., 1995. However, erythrocytes
also have a high concentration of FKBP12 and tacrolimus is exten-
sively distributed within the red blood cell compartment (Biagiotti
et al., 2011). Approximately 80% (range 70–95%) of tacrolimus
measured in whole blood is distributed in erythrocytes, where it has
no immunosuppressive effect.
Since the site of action of tacrolimus is within the lymphocyte, it
seems reasonable to assume that the tacrolimus concentration within
the lymphocyte is more relevant than the whole‐blood concentration
when predicting treatment efficacy. Recent studies support this
assumption (Capron et al., 2016; Han et al., 2016). Several methods
have been developed and validated for quantification of tacrolimus in
peripheral blood mononuclear cells (PBMCs;i.e., lymphocytes and
monocytes; Capron et al., 2007; Capron et al., 2009; Lemaitre, Antignac,
& Fernandez, 2013; Pensi et al., 2015). However, these analytical
methods are complicated and time consuming compared with whole
blood tacrolimus assays. The PBMC isolation in these methods is in
general performed using the Ficoll separation technique on ice, to
prevent tacrolimus efflux from the cells. In some centers, purification
of the cell pellet is performed to decrease contamination with eryth-
rocytes. The need for sample purification is, however, not clear.
Thereafter, 1–10 million PBMCs are used for the complicated and
time‐consuming sample preparation and the tacrolimus concentra-
tions are measured on immunoassay or UPLC–MS/MS (Capron
et al., 2007; Capron et al., 2009; Lemaitre et al., 2013; Pensi et al.,
2015). Here, a more rapid and sensitive UPLC–MS/MS assay for the
measurement of the tacrolimus concentration in PBMCs is described.
In this method we improved the cell isolation, investigated the need
for isolation on ice and the effect of erythrocyte purification of the
cell pellet, and developed a new, more rapid and sensitive sample
preparation for UPLC–MS/MS analysis.TABLE 1 Concentrations of the calibration standards
Analyte LLOQ (μg L−1) S1 (μg L−1) S2 (μg L−1) S3 (μg L−1)
Tacrolimus 0.1 0.1 0.5 1.02 | MATERIALS AND METHODS
2.1 | Chemicals and reagents
Tacrolimus and ammonium acetate were purchased from Sigma‐Aldrich
Chemie B.V. (Zwijndrecht, theNetherlands) and 13C2H4‐tacrolimus from
Alsa Chim (Illkirch‐Graffenstaden, France). MagSiMUS‐TDMprep Kit
from MagnaMedics containing MagSiMUS‐TDMprep Type I Particle
Mix (Beads), Reconstitution Buffer IS, Organic Precipitation Reagent
VI (OPR VI) for methanol‐based protein precipitation and lysis buffer
for whole blood were purchased from MagnaMedics Diagnostics B.V.
(Geleen, the Netherlands). Water was purified using a MilliPore Advan-
tage A10 System. Methanol and formic acid were purchased from
Biosolve BV (Valkenswaard, the Netherlands). Human tacrolimus‐free
PBMCs were isolated using Ficoll‐Paque Plus (GE Healthcare Bio‐
Sciences AB, Uppsala, Sweden) from buffy coats in citrate blood
obtained from Blood bank Sanquin (Rotterdam, the Netherlands). Red
blood cell lysis buffer from eBioscience (Affimetrix Inc., San Diego, CA,
USA) was used for purification. Cells were counted using a
SysmexXOP‐300 cell counter (Sysmex Corporation, Kobe, Japan).2.2 | Stock solutions, calibration standards, quality
control samples and internal standard
The calibration standards and quality controls were prepared using
different stock solutions and tacrolimus‐free PBMCs. Stock solutions
of tacrolimus and 13C2H4‐tacrolimus (500mg L
−1) were prepared by
dissolving 25mg in 50mL of methanol. Stock solutions were stored
at −80°C. Two working solutions were prepared by diluting the stock
solutions with human tacrolimus‐free PBMCs isolated from buffy
coats. The concentrations of the lower limit of quantitation (LLOQ)
standard and calibration standards are given in Table 1 and the con-
centrations of the quality controls are given in Table 2. Calibration
standard 8 and quality control high (QC H) were prepared by diluting
the working solution with human tacrolimus‐free PBMCs. Calibration
standards 5–7 were prepared by diluting standard 8; calibration stan-
dards 3 and 4 were prepared by diluting standard 5; calibration stan-
dard 2 was prepared by diluting standard 3; and calibration standard
1 was prepared by diluting standard 2. All calibration standards were
diluted with human tacrolimus‐free PBMCs. Quality controls low and
medium (QC L and QC M) were prepared by diluting QC H with
tacrolimus‐free human PBMCs. A 50 μL aliquot of the prepared
standards and quality control samples were transferred into 1.5mL
safe‐lock Eppendorf tubes and stored at −80°C prior to analysis.2.3 | PBMC isolation from whole blood
The PBMC isolation for patient samples was performed using 3–4mL
heparinized blood. These samples were centrifuged for 7min at 350g.S4 (μg L−1) S5 (μg L−1) S6 (μg L−1) S7 (μg L−1) S8 (μg L−1)
2.5 5.0 10 15 25
TABLE 2 Concentrations of the quality controls
Analyte QC L (μg L−1) QC M (μg L−1) QC H (μg L−1)
Tacrolimus 0.4 8.0 20
QC L, Quality control low; QC M, quality control medium; QC H, quality
control high.
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followed by resuspension of the residue with the same volume of
phosphate‐buffered saline (PBS). The resuspended blood was pipetted
in 12mL Leucosep tubes filled with 3mL Ficoll‐Paque Plus. Samples
were centrifuged for 20min at 850g without brakes. The PBMC layer
was isolated carefully and washed with PBS at room temperature.
After isolation of the PBMC pellet, a lysing step was performed by
adding red blood cell (RBC) lysis buffer. After this lysing step the cells
were washed twice in PBS. The cells were pelleted by centrifugation
7min at 750g. After the centrifugation step, the cells were resus-
pended in PBS. The whole isolation procedure was performed at room
temperature. After isolation, the PBMCs were counted and snap
frozen in liquid nitrogen and stored at −80°C in aliquots of 1 × 106
cells per vial.
2.3.1 | Isolation at room temperature
To investigate the need to isolate PBMCs on ice to prevent the tacro-
limus efflux, we compared the results of both methods. Six different
samples from renal transplant patients were split into two parts after
isolation of the PBMC with Ficoll‐Paque Plus at room temperature.
One part was further isolated on ice and the other part at room
temperature. Both samples were analyzed using the described method
and the results were compared.
2.3.2 | Washing steps for red blood cell lysis
To purify the isolated PBMCs from disturbing red blood cells, a
washing step with RBC lysis buffer was evaluated according to the
manufacturer's instructions. At first, the influence of adding one
washing step was tested. Furthermore, to investigate the number of
washing steps needed to purify the sample a comparison between one
washing steps and up to three washing steps was performed. Ten whole
blood samples from renal transplant patients, containing tacrolimus,
were prepared for analysis after one, two and three washing steps. The
results were compared to find the minimum number of washing steps
needed to eliminate the disturbing red blood cells from the isolated
PBMC's. Cells were counted using a SysmexXOP‐300 cell counter.2.4 | Sample preparation
For the sample preparation, the reagents kit containing MagnaMedics
Type I Particle Mix Beads, reconstitution buffer IS, organic precipita-
tion reagent VI and lysis buffer were used. This sample preparation
is based on paramagnetic beads which eliminates interfering proteins,
phospholipids and salts from whole blood, plasma and serum prior to
analysis. The protein precipitation is collected through magnetic sepa-
ration. This results in fast sample preparation. This sample preparation
was equal for the calibration standards, the quality control samplesand the patient samples. Aliquots of 50 μL, containing 1 × 106 cells,
were incubated for 1min with 30 μL lysis buffer to complete lysis
of the cells spiked with 20 μL of the internal standard solution
(10 μg L−1 tacrolimus 13C2H4), 40 μL of the MagnaMedics Beads and
175 μL OPR VI, and mixed by vortexing for 10 s. Samples were then
centrifuged at 1811g for 5min. A 200 μL aliquot of the supernatant
was transferred to an autosampler insert vial. A volume of 10 μL was
injected into the LC system. The concentration measured in the
sample was reported in μg L−1. This concentration was multiplied
50 times to calculate the amount of tacrolimus per picogram in a pellet
of 50 μL containing 1 million PBMCs.2.5 | Instrumentation
A Waters Acquity UPLC–MS/MS system (Waters Corp., Milford, MA,
USA) consisting of an Acquity binary solvent manager (chromato-
graphic pump), a sample manager (autosampler) and a column manager
was used. The UPLC was connected to a Waters TQ‐S micro mass
spectrometer with a triple quadrupole. The software programs
Masslynx™ V4.1 and Targetlynx V4.1 were used for data processing.
2.5.1 | UPLC conditions
Chromatographic separation was performed on a reversed phase
Waters Acquity UPLC BEH C18 column (1.7 μm, 50 × 2.1mm) at a
temperature of 60°C. A gradient elution was applied using mobile
phase consisting of solvent A, 2mM ammonium acetate and 0.1%
formic acid in 1 L milliQ water, and 2mM ammonium acetate and
0.1% formic acid in 1 L methanol as solvent B. The flow rate was set
at 0.5mLmin−1. The initial condition was 45% solvent A and 55%
solvent B. Solvent B increased to 70% in 0.6min, then rapidly changed
to 90% B in 0.1min, then solvent B increased to 100% in 0.1min and
finally the ratio of solvent A:B was 45:55 to equilibrate at starting
conditions for 2.2min. The total runtime was 3min. The injection
volume was 10 μL.
2.5.2 | MS/MS conditions
To determine the optimal MS settings for tacrolimus and the internal
standard tacrolimus 13C2H4, solutions of each compound were pre-
pared with a concentration of 1mg L−1 in methanol. These solutions
were directly injected into the MS without chromatographic separa-
tion. Parameters as the cone voltages and collision energies were
optimized for each compound. The product ion with the highest
sensitivity was selected as the quantifier.
The MS was operated in the positive ion mode with a capillary
voltage of 1.0 kV, source block temperature of 150°C and desolvation
temperature 350°C, and desolvation gas flow was delivered at
900 L/h. The collision was performed by using argon gas and the
collision cell pressure was 3.4 × 10−3 mbar. The dwell time for each
transition was 50ms. Data acquisition was performed via multiple
reaction monitoring. The optimal settings were obtained by infusion
experiments with a mixture of 1 μgmL−1 of tacrolimus and 13C2H4‐
tacrolimus in methanol. The optimized settings for the multiple
reaction monitoring of each analyte are summarized in Table 3.
TABLE 3 MS/MS settings
Analyte Parent ion (m/z) Product ion (m/z) ESI mode Cone voltage (V) Collision energy (eV)
Tacrolimus 821.6 768.5 + 31 18
Tacrolimus 13C–2H4 826.6 773.5 + 31 18
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The validation of the method was based on the Food and Drug
Administration guidelines for bioanalytical validations, revised 2001
(US Department of Health and Human Services, 2001). The following
validation parameters were investigated.2.6.1 | Linearity
To investigate the linearity of the method, a calibration curve of each
analyte was prepared and analyzed containing eight calibration stan-
dards in duplicate. The calibration curve defines the relation between
the concentration of the analyte and the ratio of the response of the
analyte and the response of the internal standard. The calibration
curve consists of a blank sample without internal standard and a zero
sample (blank with internal standard), and eight nonzero samples
covering the expected range, including LLOQ. Each standard was
prepared and analyzed in duplicate. The correlation coefficient (r) has
to be at least 0.995 for tacrolimus (US Department of Health and
Human Services, 2001).2.6.2 | LLOQ and ULOQ
The LLOQ was determined by measuring six replicates of the LLOQ
standard which has the same concentration as the lowest standard
on the calibration curve. The precision of the calculated concentration
should be <20% and the accuracy should be between 80 and 120%.
The highest standard on the calibration curve was used to decide on
the upper limit of quantitation (ULOQ). The precision of the ULOQ
should be <15% and the accuracy between 85 and 115% of the
theoretical concentration (US Department of Health and Human
Services, 2001).TABLE 4 Differences between isolation of peripheral blood mono-2.6.3 | Accuracy
The accuracy was determined by measuring three concentrations, QC
H, QC M and QC L, 6‐fold on the same day. The bias should not
exceed 15% and the relative standard deviation should be within
15% (US Department of Health and Human Services, 2001).
nuclear cells (PBMCs) at room temperature and on ice
Sample
Tacrolimus (pg/million cells)
Difference (%)Room temperature On ice
1 92 86 7.0
2 58 68 −14.6
3 43 47 −7.1
4 35 30 14.3
5 55 36 50.0
6 42 45 −6.72.6.4 | Intra‐ and inter‐day precision
The intra‐ and inter‐day precision was calculated by measuring six
replicates at three concentration levels (QC L, M and H) in duplicate.
The intra‐day precision was measured on the same day and the
inter‐day precision was measured on six different days. The accuracy
should be between 85 and 115% and the precision within the 15%
(US Department of Health and Human Services, 2001).2.6.5 | Stability
To investigate the autosampler stability, three QC levels were stored
at 15°C after the first injection, for 24, 48, 72, 96 and 120 h. The con-
centrations were compared with the concentrations of the QCs at the
first time. The recovery should be between 90 and 110%. The long‐
term stability of stored calibration standards and QC samples in the
freezer (−80°C) was investigated after a period of 12months. The
recovery should be between 90 and 110%.
2.6.6 | Matrix effects
To investigate the matrix effects, the method of Matuszewski
(Matuszewski, Constanzer, & Chavez‐Eng, 2003) was used. Five
different batches of human tacrolimus‐free PBMCs were collected.
Three sets of samples were prepared (sets A–C). In set A, six different
samples were prepared in milliQ water; two blanks and QC L and QC
H. In set B, blanks, QC L and QC H were prepared in five different
human tacrolimus‐free PBMCs. Tacrolimus was added after sample
preparation. In set C, blanks, QC L and QC H were prepared in five
different human tacrolimus‐free PBMCs, and tacrolimus was added
before sample preparation. Blanks, QC L and QC H for each set were
prepared in duplicate. Recovery was defined as the ratio of the results
of set B and C (C/B × 100%). Process efficiency is the ratio from set A
and set C (C/A × 100%). Matrix effects were defined by the ratio of
set A and set B (B/A × 100%). Matrix effects, recoveries and process
efficiencies should be between 80 and 120%.3 | RESULTS
3.1 | Sample preparation
3.1.1 | Isolation at room temperature
The differences between isolation of PBMCs at room temperature and
on ice are presented in Table 4. No structural differences as a result of
cell efflux were seen. The median difference was 0.15% (p = 0.625).
BAHMANY ET AL. 5 of 83.1.2 | Washing steps for red blood cell lysis
Without an RBC lysis washing step some samples showed a light red
color, which is probably due to the presence of red blood cells in the
pellet. A first washing step using RBC lysis buffer resulted in a
decrease in the concentration of intracellular tacrolimus of 38–58%.
As a consequence, the differences between one, two and three
washing steps were compared (Table 5). The average ratio between
one and three washing steps was 0.9 (SD 0.12). We concluded that
one washing step using RBC lysis buffer was enough to purify the
PBMC pellet.3.2 | Validation
The RSD of accuracy, intra‐ and inter‐day precision data were within
the requirement of an RSD <15%. The results are shown in Table 6.3.2.1 | Linearity
The calibration curve of tacrolimus was successfully validated; the
correlation coefficient (r) was 0.999 over the concentration range of
0.1–25 μg L−1 fitted by a 1/x weighting factor and excluding the origin.
This concentration range corresponds to 5–1250 pg/L × 106 cells. We
saw that the concentrations of the clinical samples were within this
calibration range.3.2.2 | LLOQ and ULOQ
The precision of the LLOQ standard 0.1 μg L−1 was −5% with an RSD
of 11% which is within the requirement of 20% for the precision and
15% for the RSD. The ULOQ was determined as 25 μg L−1. The LLOQ




Ratio 1/31× lysis 3× lysis
1 160 189 0.85
2 130 133 0.98
3 112 112 1.00
4 75 96 0.78
5 57 56 1.02
6 34 39 0.87
7 46 52 0.88
8 56 81 0.69
9 37 43 0.86
10 42 40 1.05
TABLE 6 Validation results
Analyte QC Concentration (μg L−1) Accuracy RSD (%
Tacrolimus L 0.4 −4.5
M 8.0 −1.2
H 20 1.5concentration corresponds to 1250 pg/L × 106 cells. The correspond-
ing chromatogram is presented in Figure 1.
3.2.3 | Stability
The results after 24 h in the autosampler at 15°C were not within the
requirement. The recoveries of QC L were not within the require-
ments (89.7 and 87.5%). The recoveries of QC M (101.6 and
101.3%) and QC H (99.3 and 101.5%) were within the requirements.
Extracts must be measured within 24 h.
The recovery of three QC levels after 12months of storage were
within the requirements. Calibration standards and QC samples were
stable for at least 12months at −80°C.
3.2.4 | Matrix effects
Matrix effects, recoveries and process efficiency were between 80
and 120% for QC H. QC L did not meet the requirements. Coefficients
of variation were <5% for both QC L and QC H. The results are
presented in Table 7.4 | CLINICAL APPLICATION
To investigate whether the described assay can be used to determine
the intracellular concentration of tacrolimus in isolated PBMCs for
clinical purposes, a pilot experiment was performed in a renal trans-
plant recipient. For this experiment, 4 blood samples taken just before,
and 2, 4 and 8 h after oral tacrolimus administration were used. In
Figure 2 the tacrolimus whole blood concentrations compared with
the intracellular concentrations over a dose interval are presented.
To measure the whole blood concentrations, a method published by
Waters was used (Annesley et al., 2013). The whole blood/PBMC
concentration ratio remained stable between 0.15 and 0.17 over this
concentration–time profile.
For the experiments testing the separation of PBMCs at room
temperature and the number of washing steps with RBC lysis needed,
we used samples from renal transplant patients treated with
tacrolimus. The assay resulted in reproducible results in these patient
samples.5 | DISCUSSION
The development, optimization and validation of an accurate and
specific method for the determination of the concentration of
tacrolimus in PBMCs is described. The method described is faster
and has a lower or equal LLOQ compared with other methods that
were previously described in literature (Capron et al., 2007; Capron




FIGURE 2 Tacrolimus concentration–time profile in whole blood vs.
peripheral blood mononuclear cells (PBMCs)
FIGURE 1 Chromatogram of the LLOQ standard (0.10 μg L−1) of tacrolimus with the internal standard 13C2H4‐tacrolimus. The retention time and
peak‐area are given on top of the peak
TABLE 7 Matrix effects
Set QC L QC H
Matrix effect (%) B/A 136 112
Recovery (%) C/B 45 101
Process efficiency (%) C/A 61 112
CV (%) n = 10 B 0.8 1.5
CV (%) n = 10 C 2.3 4.0
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clinical purposes and it may outperform traditional TDM using
whole blood concentrations (Annesley et al., 2013) when predicting
the clinical response to tacrolimus therapy of transplant recipients.5.1 | PBMC isolation
During the development of our assay, we investigated several
aspects. First, we investigated the need to isolate PBMCs on ice,
which is supposed to prevent efflux of tacrolimus during the
isolation procedure. In our comparison with isolation at room tem-
perature we did not see this supposed decrease in concentration.
As a consequence, the isolation of PBMCs can be performed at
room temperature, which facilitates this complicated process
compared with other methods (Capron et al., 2007; Capron et al.,
2009; Lemaitre et al., 2013; Pensi et al., 2015). The results are
shown in Table 4.
After isolation of PBMCs using Ficoll technique, a slight red
color was seen in some pellets. As tacrolimus distributes ~80% to
red blood cells, this might disturb the analysis. Addition of a
washing step with RBC lysis resulted in a decrease in tacrolimus
concentration of 38–58% in these samples, indicating that an
additional purification step to lose these red blood cells is needed.
One washing step was the optimum, as we did not see any
structural differences after addition of additional washing steps,
which is shown in Table 5. Pensi et al. (2015) used ammonium salt
solution to purify the sample. Other methods did not perform a
purification washing step (Capron et al., 2007; Capron et al.,
2009; Lemaitre et al., 2013).
BAHMANY ET AL. 7 of 85.2 | Sample preparation and measurement
Several methods have been published (Capron et al., 2007; Capron
et al., 2009; Lemaitre et al., 2013; Pensi et al., 2015) to determine
the concentration of tacrolimus in PBMCs but none of these methods
makes use of an internal standard which is identical in physical and
chemical properties to the analyte. This method is unique with tacro-
limus 13C2H4 as internal standard for the determination of tacrolimus
in PBMCs. In comparison with our method, the published methods
contain a time‐consuming sample preparation, because solid‐phase
extraction and evaporation combined with a reconstitution step was
applied. Besides the time‐consuming sample preparations, higher
sample volumes were used of at least 500 μL up to a maximum of
1.1mL. The amount of cells at each session in earlier published
methods varied from 1 × 106 and 6 × 106 to 1 × 107 cells. In that
respect, our method is at the lower end of the range using 1 × 106
cells (Capron et al., 2007; Capron et al., 2009; Lemaitre et al., 2013;
Pensi et al., 2015).
The injection volumes also varied from 20 to 25 μL, which is more
than in our method. The present method is also more sensitive, as the
earlier published methods have a higher or equal LLOQ, even though
they use a higher sample volume, higher concentration of the PBMCs
and higher injection volume. The sample preparation of the other
published methods also includes also a solid‐phase extraction and
evaporation step, which could decrease the recovery of the analyte.
To our knowledge, this method is the first validated LC–MS/MS
method to determine tacrolimus in PBMCs without a time‐consuming
sample preparation step, including a sample preparation with
MagnaBeads, a lower sample volume, lower injection volume and a
very short total runtime.
Despite the good results of this method, a recommendation
can be made concerning the autosampler stability. The recovery
of QC L did not meet the requirements after 24 h. Adjustment of
the autosampler temperature to 10 or 5°C could be a solution to
meet the recovery requirements. The stability during the sample
preparation has not been determined, because in our setting
samples are always prepared and analyzed within 1 h after sample
collection.
Matrix effects experiments showed higher responses for QC L in
set B (when tacrolimus was added after sample preparation). This
may be caused by concentration loss of tacrolimus during the sample
preparation. This gives a larger deviation at the lower concentrations
in comparison with higher concentrations (QC H). In practice, this will
not cause a problem, because tacrolimus is added before sample
preparation for calibration standards and QCs, which means that there
will be a correction for any loss of tacrolimus concentration during the
sample preparation. Coefficients of variation were <5% for both QC L
and QC H.5.3 | Clinical application
The data obtained from the renal transplant patient suggests that the
dynamics of the tacrolimus concentrations in PBMCs run parallel to
the pharmacokinetic profile in whole blood. We did not observe adelay in reaching the maximum concentrations in PBMCs in this
patient. Apparently, tacrolimus reaches the interior of PBMCs quite
easily, either by diffusion or by active transport. Possibly by drawing
samples at closer time intervals, for example every 15min, a more
subtle delay in reaching concentrations in PBMCs might be detected.
The ratio of the intracellular and whole blood tacrolimus concentration
differs between patients (see Figure 2). These results would suggest
that the ratio determined for one timepoint can be extrapolated to
the whole AUC. However, more research is needed to confirm this
finding and investigate if this ratio could be extrapolated within one
patient over a longer time period.6 | CONCLUSION
In conclusion, the validation and development of this rapid and sensi-
tive LC–MS/MSmethod for the measurement of tacrolimus concentra-
tions in PBMCs was successfully finalized. The isolation of PBMCs can
be performed at room temperature without consequences for the
tacrolimus concentration. A red blood cell washing step has to be
performed to purify the sample from contamination of tacrolimus
bound to erythrocytes. In comparison with other assays, the method
presented here is the first one without a time‐consuming sample
preparation after the isolation of the PBMCs, using MagnaBeads
sample preparation with also a high sensitivity (LLOQ= 0.1 μg L−1
which corresponds to 5 pg/L × 106 cells). Finally, our method has
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